Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma

Pignon, T.; S, Ruggieri; Boutin, C; Gouvernet, Joanny; M, Irisson; P, Juin; Astoul, Philippe

doi:10.1002/(sici)1097-0142(19990515)85:10<2144::aid-cncr8>3.0.co;2-6

Cited by 5 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Better survival was found in patients with NSCLC presenting with an objective response to induction chemotherapy before surgery or to treatment for locoregionally advanced NSCLC, induction chemotherapy before radiotherapy, chemoradiotherapy, or radiotherapy alone [59][60][61][62][63][64]. The level of evidence was from analyses of secondary objectives of randomised trials published on each topic (table 6) and phase II studies [66][67][68][69][70][71][72][73][74]. We found only one study in SCLC showing that patients with complete response had longer survival than those with partial response or no change, those progressing under firstline treatment with chemotherapy or chemoradiotherapy having the worst prognosis [65].…”

Section: Question 1: Can the Criteria Of Pfs Ttp And Dfs Be Used To mentioning

confidence: 92%

Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations

Berghmans¹,

Pasleau²,

Paesmans³

et al. 2011

Eur Respir J

View full text Add to dashboard Cite

The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria (surrogate markers), instead of survival, in determining treatment efficacy in patients with lung cancer. Initially, the level of evidence for the use of overall survival to evaluate treatment efficacy was reviewed. Nine questions were then formulated by the ELCWP. After reviewing the literature with experts on these questions, it can be concluded that overall survival is still the best criterion for predicting treatment efficacy in lung cancer. Some intermediate criteria can be early predictors, if not surrogates, for survival, despite limitations in their potential application: these include time to progression, progression-free survival, objective response, local control after radiotherapy, downstaging in locally advanced nonsmall cell lung cancer (NSCLC), complete resection and pathological TNM in resected NSCLC, and a few circulating markers. Other criteria assessed in these recommendations are not currently adequate surrogates of survival in lung cancer.

show abstract

Section: Question 1: Can the Criteria Of Pfs Ttp And Dfs Be Used To mentioning

confidence: 92%

Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations

Berghmans¹,

Pasleau²,

Paesmans³

et al. 2011

Eur Respir J

View full text Add to dashboard Cite

show abstract

Locally advanced non-small cell lung cancer

Cohen

Vokes

2001

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Locally advanced non-small cell lung cancer remains a paradoxical entity to manage. Although this type of cancer is confined to the thorax and is ostensibly curable, most patients presenting at this stage of disease eventually succumb to it. The accepted therapy presently includes chemotherapy and radiation. The exact agents, schedules, and combinations need to be defined further, although cisplatin has become the widely viewed standard cytotoxic drug in this setting. Notwithstanding, newer chemotherapeutic and biologic agents are being extensively tested to find less toxic options with greater efficacy. Drugs that are gaining widespread approval include carboplatin, paclitaxel, gemcitabine, and vinorelbine. At the same time, advances in radiation therapy are triggering a revolution in dose intensity and scheduling that will one day offer superlative local control.

show abstract

Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer

Oka

Fukuda

Kinoshita³

et al. 2001

European Journal of Cancer

View full text Add to dashboard Cite

Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma

Cited by 5 publications

References 34 publications

Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations

Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations

Locally advanced non-small cell lung cancer

Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer

Contact Info

Product

Resources

About